CompaniesInvestorsPeople
Home
Loading

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

Get in Touch

  • Contact

  • Request a Demo

  • Request Data Updates

  • Add a Company

Research

  • Companies

  • Investors

  • People

aVenture

  • Download App

  • Pricing

Download the aVenture Research beta for iOS and iPadOSDownload aVenture Research on the Mac App Store

Resources

  • Documentation

  • Use Cases

  • CLI

  • MCP

  • Feature Requests

  • Sitemap

Member

Backed by

Ask AI about aVenture

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy · Terms of Service

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading
Loading
Home
News
Cameroonian healthtech Waspito gets $2.5M seed extension to scale, tap offline patients

From TechCrunch

By Annie Njanja

November 22, 2023

Cameroonian healthtech Waspito gets $2.5M seed extension to scale, tap offline patients

Cameroonian health startup Waspito has secured a $2.5 million seed extension from DP World through Newtown Partners, Saviu Ventures, AAIC Investment, Axian ventures and CFAO’s Health54 to spur its growth in the Francophone region. Waspito is a health-focused social network that allows users (patients) to access and consult with verified doctors over video calls. Additionally, […]

© 2023 TechCrunch. All rights reserved. For personal use only.

Most Recent

Foxconn agrees to acquire a 50% stake in Mitsubishi's automotive components unit for ~$727M; Mitsubishi will provide autonomous tech for Foxconn's EV platforms

Hon Hai Precision Industry Co. is paying ¥115 billion ($727 million) for a 50% stake in Mitsubishi Electric Corp.'s automotive-components unit …

Oct 19, 2026

Robot factories and hypersonic missiles: JPMorgan Chase’s first $5 billion of defense investments

With $5 billion already deployed off its balance sheet, JPMorgan Chase is racing ahead on direct investments in defense tech, hardware and supply chains.

Oct 19, 2026

Pax8 launches 8os to let IT partners govern AI agents and 8bot as a managed AI co-worker

Small business software marketplace Pax8 Inc. today launched 8os, an operating system that lets its information technology service provider partners govern the artificial intelligence agents running inside their customers’ businesses. A second product, 8bot, gives those customers’ employees a manage

Oct 19, 2026

China's CXMT shares fall nearly 8% as investors look past chipmaker's profit turnaround

CXMT shares fell over 6% on Monday after the company released its earnings forecast for the first nine months of 2026.

Oct 19, 2026

Similar Posts

Nigeria’s Remedial Health gets QED backing in $12M round

Remedial Health, a Nigerian startup digitizing pharmacies and bringing efficiency to the pharmaceutical value chain, has raised $12 million Series A equity-debt funding, to scale operations in the West African country. Fintech VC firm QED Investors co-led the round, banking on embedded financial opportunities like payments, and lending in the pharmaceutical sector. This is QED’s […]

Jul 31, 2023

Sprinter Health raises $55M to expand its at-home healthcare service

The Series B was led by General Catalyst, with Andreessen Horowitz, Regents of the University of California, Google Ventures, and Accel also investing.

May 15, 2025

India’s HealthPlix raises $22M to accelerate growth and enhance healthcare delivery

HealthPlix, an Indian startup offering its in-house platform for doctors to help record patient data digitally, has raised $22 million in fresh investment to broaden its reach in the country and allow more doctors to utilize its software to offer improved care to their patients. In India, roughly 300,000 doctors practice medicine regularly. However, this […]

Mar 14, 2023

India’s HealthPlix raises $22M to accelerate growth and enhance healthcare delivery

HealthPlix, an Indian startup offering its in-house platform for doctors to help record patient data digitally, has raised $22 million in fresh investment to broaden its reach in the country and allow more doctors to utilize its software to offer improved care to their patients. In India, roughly 300,000 doctors practice medicine regularly. However, this […]

Mar 14, 2023